IL-15-based molecules and methods of use thereof
US-11173191-B2 · Nov 16, 2021 · US
Multimeric IL-15 soluble fusion molecules and methods of making and using same
US12371472B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12371472-B2 |
| Application number | US-202318498430-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2023 |
| Priority date | Sep 21, 2010 |
| Publication date | Jul 29, 2025 |
| Grant date | Jul 29, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
First claim
Opening claim text (preview).
What is claimed is: 1. A method of stimulating CD8+ memory T cells and effector NK cells in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an Interleukin-15N72D: Interleukin-15 receptor alpha Sushi/Fc (IL-15N72D: IL-15RαSu/Fc; ALT-803) complex, wherein the complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules. 2. The method of claim 1 , wherein the effective amount is between 1 μg/kg and 20 μg/kg. 3. The method of claim 2 , wherein the effective amount is 15 μg/kg. 4. The method of claim 1 , wherein the effective amount is between 20 μg/kg and 100 μg/kg. 5. The method of claim 4 , wherein the effective amount is 30 μg/kg. 6. The method of claim 1 , wherein the pharmaceutical composition comprising the IL-15N72D: IL-15RαSu/Fc complex is administered once per week. 7. The method of claim 1 , wherein the pharmaceutical composition is administered systemically, intravenously, subcutaneously or by instillation into the bladder. 8. The method of claim 1 , wherein the subject has increased levels of serum Interferon gamma (IFNγ). 9. The method of claim 1 , wherein the subject has a neoplasia. 10. The method of claim 9 , wherein the neoplasia is beta cell lymphoma, urothelial/bladder carcinoma, melanoma, breast cancer, multiple myeloma, or pancreatic cancer. 11. The method of claim 1 , wherein the subject has a viral infection.
Assignees
Inventors
Classifications
Fusion polypeptide · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
against material from animals or humans · CPC title
IL-13 to IL-16 · CPC title
IL-15 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12371472B2 cover?
- The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
- Who is the assignee on this patent?
- Altor Bioscience Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/7155. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).